{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T11:19:31Z","timestamp":1764587971771,"version":"build-2065373602"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000890","name":"National Multiple Sclerosis Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000890","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005565","name":"Janssen Biotech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011944","name":"School of Public Health, University of California Berkeley","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011944","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005620","name":"North Carolina GlaxoSmithKline Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005620","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1053\/j.ajkd.2018.12.025","type":"journal-article","created":{"date-parts":[[2019,2,11]],"date-time":"2019-02-11T18:05:28Z","timestamp":1549908328000},"page":"256-262","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Repository Corticotropin Versus Glucocorticoid for Nephrotic Syndrome: When Will We See the Evidence?"],"prefix":"10.1053","volume":"74","author":[{"given":"Daniel M.","family":"Hartung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirbee","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis N.","family":"Bourdette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1053\/j.ajkd.2018.12.025_bib1","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1007\/s12325-017-0569-9","article-title":"Clinical and economic evaluation of repository corticotropin injection: a narrative literature review of treatment efficacy and healthcare resource utilization for seven key indications","volume":"34","author":"Philbin","year":"2017","journal-title":"Adv Ther"},{"issue":"5","key":"10.1053\/j.ajkd.2018.12.025_bib3","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2215\/CJN.03380318","article-title":"Does the kidney biopsy portend the future of nephrology?","volume":"13","author":"Gilbert","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2018.12.025_bib4","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000339287","article-title":"Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trial","volume":"36","author":"Bomback","year":"2012","journal-title":"Am J Nephrol"},{"key":"10.1053\/j.ajkd.2018.12.025_bib5","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2147\/DDDT.S17521","article-title":"Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel","volume":"5","author":"Bomback","year":"2011","journal-title":"Drug Design Dev Ther"},{"key":"10.1053\/j.ajkd.2018.12.025_bib6","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12882-016-0241-7","article-title":"Acthar gel in the treatment of nephrotic syndrome: a multicenter retrospective case series","volume":"17","author":"Madan","year":"2016","journal-title":"BMC Nephrol"},{"issue":"8","key":"10.1053\/j.ajkd.2018.12.025_bib7","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/ndt\/gfu069","article-title":"A\u00a0pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar(R) Gel) in nephrotic syndrome due to idiopathic membranous nephropathy","volume":"29","author":"Hladunewich","year":"2014","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"10.1053\/j.ajkd.2018.12.025_bib8","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.2215\/CJN.02840313","article-title":"Treatment of idiopathic FSGS with adrenocorticotropic hormone gel","volume":"8","author":"Hogan","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"10.1053\/j.ajkd.2018.12.025_bib9","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.2215\/CJN.06890618","article-title":"Adrenocorticotropic hormone for childhood nephrotic syndrome: the ATLANTIS randomized trial","volume":"13","author":"Wang","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2018.12.025_bib10","article-title":"Questcor finds profits, at $28,000 a vial","author":"Pollack","year":"2012","journal-title":"New York\u00a0Times"},{"key":"10.1053\/j.ajkd.2018.12.025_bib11","article-title":"The obscure drug with a growing Medicare tab","author":"Ornstein","year":"2014","journal-title":"ProPublica"},{"key":"10.1053\/j.ajkd.2018.12.025_bib12","article-title":"Top Acthar prescribers in Medicare have ties to its maker","author":"Ornstein","year":"2014","journal-title":"ProPublica"},{"key":"10.1053\/j.ajkd.2018.12.025_bib13","article-title":"A\u00a0costly drug, missing a dose of disclosure","author":"Morgenson","year":"2017","journal-title":"New York Times"},{"key":"10.1053\/j.ajkd.2018.12.025_bib14","article-title":"Questcor Acquired By Mallinckrodt for $5.6 Billion","author":"Alpert","year":"2014","journal-title":"Barron's"},{"issue":"3","key":"10.1053\/j.ajkd.2018.12.025_bib15","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.chest.2015.12.020","article-title":"Finding common ground: professionalism and Acthar prescribing practices","volume":"149","author":"Liss","year":"2016","journal-title":"Chest"},{"issue":"11","key":"10.1053\/j.ajkd.2018.12.025_bib16","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1001\/jamainternmed.2017.3631","article-title":"Trends and characteristics of US Medicare spending on repository corticotropin","volume":"177","author":"Hartung","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"1","key":"10.1053\/j.ajkd.2018.12.025_bib17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.chest.2017.09.042","article-title":"Higher priced older pharmaceuticals: how should we respond?","volume":"153","author":"Irwin","year":"2018","journal-title":"Chest"},{"issue":"2","key":"10.1053\/j.ajkd.2018.12.025_bib18","doi-asserted-by":"crossref","first-page":"e180482","DOI":"10.1001\/jamanetworkopen.2018.0482","article-title":"Industry payments to physician specialists who prescribe repository corticotropin","volume":"1","author":"Hartung","year":"2018","journal-title":"JAMA Network Open"},{"issue":"4","key":"10.1053\/j.ajkd.2018.12.025_bib21","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1001\/jamainternmed.2017.8542","article-title":"Uses of H.P. Acthar Gel in the clinical setting","volume":"178","author":"Otulana","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"5","key":"10.1053\/j.ajkd.2018.12.025_bib22","first-page":"1","article-title":"Cooperative study in the evaluation of therapy in multiple sclerosis. ACTH vs. placebo--final report","volume":"20","author":"Rose","year":"1970","journal-title":"Neurology"},{"issue":"4","key":"10.1053\/j.ajkd.2018.12.025_bib23","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0022-3476(83)80606-4","article-title":"Double-blind study of ACTH vs prednisone therapy in infantile spasms","volume":"103","author":"Hrachovy","year":"1983","journal-title":"J\u00a0Pediatr"},{"issue":"3","key":"10.1053\/j.ajkd.2018.12.025_bib24","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1542\/peds.97.3.375","article-title":"High-dose corticotropin (ACTH) versus prednisone for infantile spasms: a prospective, randomized, blinded study","volume":"97","author":"Baram","year":"1996","journal-title":"Pediatrics"},{"issue":"2","key":"10.1053\/j.ajkd.2018.12.025_bib25","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1053\/j.ajkd.2005.10.016","article-title":"A\u00a0randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy","volume":"47","author":"Ponticelli","year":"2006","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1053\/j.ajkd.2018.12.025_bib26","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/jcph.582","article-title":"Pharmacodynamics and tolerability of repository corticotropin injection in healthy human subjects: a comparison with intravenous methylprednisolone","volume":"56","author":"Lal","year":"2016","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"1","key":"10.1053\/j.ajkd.2018.12.025_bib27","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/ard.30.1.91","article-title":"Comparison of effects of corticotrophin and corticosteroids on pituitary-adrenal function","volume":"30","author":"Carter","year":"1971","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1053\/j.ajkd.2018.12.025_bib28","first-page":"53","article-title":"The impact of prolonged immunosuppression on the outcome of idiopathic focal-segmental glomerulosclerosis with nephrotic syndrome in adults. A collaborative retrospective study","volume":"36","author":"Banfi","year":"1991","journal-title":"Clin Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2018.12.025_bib29","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/S0272-6386(99)70384-7","article-title":"Can prolonged treatment improve the prognosis in adults with focal segmental glomerulosclerosis?","volume":"34","author":"Ponticelli","year":"1999","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1053\/j.ajkd.2018.12.025_bib30","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/nrneph.2011.190","article-title":"The renaissance of corticotropin therapy in proteinuric\u00a0nephropathies","volume":"8","author":"Gong","year":"2011","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2018.12.025_bib31","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1177\/1756285613518599","article-title":"Mechanisms of action of ACTH in the management of relapsing forms of multiple sclerosis","volume":"7","author":"Berkovich","year":"2014","journal-title":"Ther Adv Neurol Disord"},{"author":"MedKnowledge","key":"10.1053\/j.ajkd.2018.12.025_bib33"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638619300058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638619300058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T03:22:08Z","timestamp":1759461728000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638619300058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0272638619300058"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2018.12.025","relation":{},"ISSN":["0272-6386"],"issn-type":[{"type":"print","value":"0272-6386"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repository Corticotropin Versus Glucocorticoid for Nephrotic Syndrome: When Will We See the Evidence?","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2018.12.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is a US Government Work. There are no restrictions on its use.","name":"copyright","label":"Copyright"}]}}